🚨 Clearances, Approvals, Updates, and Recommendations
FDA Grants Fast Track Designation to DOC1021 for Unresectable or Metastatic Cutaneous Melanoma
A phase 1/2 trial enrolling patients with refractory melanoma is now actively recruiting.
Addressing Concerns as FDA Pulls Proposed Tanning Bed Ban for Minors
The proposed rule, first introduced in 2015, aimed to prohibit indoor tanning for individuals under 18 because of the known cancer risks associated with UV radiation.
Codex Labs Secures Two US Patents for Steroid-Free Eczema Treatment Technology
The patented filaggrin-targeting regimen claims up to 99% atopic dermatitis relief without steroids, boosting hydration and calming itch in adults.
Global AK Awareness Day: Almirall Launches Second Annual ‘Hats On For AK’ Campaign and ‘Skin Scouts’ Initiative
The annual AK awareness campaigns spotlight hats, sun protection, and regular skin checks to catch actinic keratosis early and prevent skin cancer.
FDA Approves OTC Differin Epiduo Gel for Acne in Patients 12 and Older
The fixed-dose adapalene 0.1% and benzoyl peroxide 2.5% topical OTC gel broadens nonprescription access to a combination topical regimen that has been used as a prescription product for more than 15 years.
🧬 Big Studies and Big Data
D-MNA Hits 55% Histological Clearance in Nodular BCC at Day 57
The high-dose D-MNA cohort showed continued improvement from Day 29 to Day 57, a trajectory not observed in the device-only control arm, supporting a drug-driven mechanism of action.
Avalo Therapeutics Reports Topline Phase 2 Success for Abdakibart in Hidradenitis Suppurativa
Initial phase 2 data show abdakibart (AVTX-009) boosts HiSCR responses in moderate to severe HS, with favorable safety, paving way for phase 3.
Ruxolitinib Cream Maintains Efficacy and Safety Through 24 Weeks in Phase 3 TRuE-AD4 Trial
A 24-week trial shows ruxolitinib cream sustains control and itch relief in moderate atopic dermatitis when steroids fail, with a positive safety profile.
Three Years of Upadacitinib Data Offer Reassurance on Laboratory Safety in AD
Treatment discontinuations due to laboratory abnormalities were uncommon, occurring in 0.7% of patients at week 52 and remaining below 2% through week 140.
👥 NP/PA Connect
Resource-poor environments exist not only globally but also in everyday settings like nursing homes, prisons, foster care, and low-income households.
About one-quarter of acne-related genetic variants also contribute to IBD risk.
Listening to favorite music or white noise during cosmetic botulinum toxin injections eases pain and stress, especially for first-time patients, with simple, low-cost comfort benefits.
Researchers reported that patients with more extensive HS disease involvement experienced significantly greater financial strain.
Evidence and experience together reinforce that extended leave can restore psychological well-being and professional sustainability.
Corabotase Demonstrates Sustained Efficacy and High Patient Satisfaction in Phase 2 Glabellar Lines Study
Data presented at SCALE 2026 showed that Ipsen’s investigational recombinant neuroinhibitor achieved significant and sustained improvement in moderate to severe glabellar lines.
Bimekizumab Tops Risankizumab in PsA Head-to-Head Trial
At EULAR 2026, investigators presented head-to-head data demonstrating significantly higher joint response rates with bimekizumab compared with risankizumab in PsA.
Qtorin Rapamycin Phase 2/3 Data Support First FDA-Approved Therapy for Rare Vascular Malformations
Phase 3 SELVA and phase 2 TOIVA data show Qtorin rapamycin met primary end points for microcystic lymphatic and cutaneous venous malformations.
Zumilokibart Meets Primary and Secondary Endpoints in Phase 2 AD Trial
Apogee plans to initiate 3 phase 3 trials of zumilokibart in moderate to severe atopic dermatitis—ADventure 1, ADventure 2, and ADventure TCS—in the second half of 2026.
💡 Expert Insights
Why Gen Z is Choosing Tanning Over Skin Protection
Daniel Condie, MD, debunks common Gen Z tanning myths, warns base tans and sunscreen fears fuel early skin cancer, and explains Mohs care challenges.
Q&A: Kavita Mariwalla, MD, FAAD, on Navigating the Modern Challenges of Skin Cancer Prevention
Kavita Mariwalla, MD, FAAD, explains why melanoma is rising in young women, how tanning trends and sunscreen myths spread online, and what prevention steps work best in younger patients.
Extended-Release Oral Minoxidil Tablets Show Potential for Enhanced Hair Growth in Androgenetic Alopecia
Maryanne Makredes Senna, MD, discusses emerging data suggesting extended-release oral minoxidil tablets may improve efficacy while minimizing cardiovascular adverse effects in patients with androgenetic alopecia.
Derm Dispatch: How Diet, Probiotics, and Gut Health Could Impact the Skin
Rajani Katta, MD, and Renata Block, DMSCc, MMS, PA-C, explore how gut microbes, fiber, and fermented foods could shape eczema, acne, and rosacea—and why probiotics aren’t one-size-fits-all.
The Future of Biotech in Professional Dermatology and Skin Barrier Care
Epicutis’ Hydrobiome Serum targets post-procedure barrier repair, while CEO Max Stock explains physician-guided care and biotech’s microbiome future.
Burnout Is Often a Leadership Problem
Kathleen Moe, MD, discusses why operational dysfunction, not medicine itself, is driving physician exhaustion in dermatology and beyond.
ITK Inhibition With Soquelitinib Yields Sustained Skin Clearance Up to 90 Days Off Therapy
Albert Chiou, MD, MBA, discusses results from the phase 1 trial of soquelitinib for moderate to severe AD presented at SID 2026.
Don't Be Rash: The Sturge-Weber Foundation's 40-Year Case for Early, Coordinated Care
The SWF Clinical Care Network now includes 27 validated US sites assessed objectively for multidisciplinary capacity across dermatology, neurology, ophthalmology, mental health, and transitional care.
Skin & Psych: The Surprising Link Between the Skin and Brain in AD and Beyond
Matthew Zirwas, MD, rethinks AD as environmentally acquired barrier dysfunction, sharing psychodermatology itch strategies and highlighting patient-centered communication.
Beyond the Surface: Julie Russak, MD, FAAD, on the Clinical Role of Nutricosmetics in Women’s Wellness
Explore evidence-backed nutricosmetics and hormone-aware nutrition for women’s skin and hair—plus what to know about collagen and dosing.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.
